Last reviewed · How we verify

Positron Emission Tomography using [11C]diprenorphine

Centre Hospitalier Universitaire de Saint Etienne · Phase 1 active Small molecule Quality 0/100

Positron Emission Tomography using [11C]diprenorphine is a Small molecule drug developed by Centre Hospitalier Universitaire de Saint Etienne. It is currently in Phase 1 development. Also known as: PET.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePositron Emission Tomography using [11C]diprenorphine
Also known asPET
SponsorCentre Hospitalier Universitaire de Saint Etienne
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Positron Emission Tomography using [11C]diprenorphine

What is Positron Emission Tomography using [11C]diprenorphine?

Positron Emission Tomography using [11C]diprenorphine is a Small molecule drug developed by Centre Hospitalier Universitaire de Saint Etienne.

Who makes Positron Emission Tomography using [11C]diprenorphine?

Positron Emission Tomography using [11C]diprenorphine is developed by Centre Hospitalier Universitaire de Saint Etienne (see full Centre Hospitalier Universitaire de Saint Etienne pipeline at /company/centre-hospitalier-universitaire-de-saint-etienne).

Is Positron Emission Tomography using [11C]diprenorphine also known as anything else?

Positron Emission Tomography using [11C]diprenorphine is also known as PET.

What development phase is Positron Emission Tomography using [11C]diprenorphine in?

Positron Emission Tomography using [11C]diprenorphine is in Phase 1.

Related